Characterization of patients that can continue conservative treatment for adenomyosis

Abstract Background Historically, hysterectomy has been the radical treatment for adenomyosis. Although, some patients may not want to have their uterus removed, patients often have to no choice but to request hysterectomy during conservative treatment. The factors necessitating these hysterectomies remain unknown. The purpose of this study was to determine which patients can continue conservative treatment for adenomyosis. Methods We selected women diagnosed with adenomyosis and provided with conservative treatment at the Kindai University Hospital and Osaka Red Cross Hospital in Osaka Japan from 2008 to 2017. Age at diagnosis, parity, uterine size, subtype of adenomyosis, type of conservative treatment, and timing of hysterectomy for cases with difficulty continuing conservative treatment were examined retrospectively. Results A total of 885 patients were diagnosed with adenomyosis, and 124 started conservative treatment. Conservative treatment was continued in 96 patients (77.4%) and hysterectomy was required in 28 patients (22.6%). The cumulative hysterectomy rate was 32.4%, and all women had hysterectomy within 63 months. In the classification tree, 82% (23/28) of women aged 46 years or younger were able to continue conservative treatment when parity was zero or one. In those with parity two and over, 95% (20/21) of those aged 39 years and older had hysterectomy. Conclusions Patients who continue conservative treatment for approximately 5 years are more likely to have successful preservation of the uterus. Multiparity and higher age at diagnosis are factors that contribute to hysterectomy after conservative treatment. Parity and age at diagnosis may be stratifying factors in future clinical trials of hormone therapy.

Download Full-text

Characterization of patients that can continue conservative treatment for adenomyosis

10.1101/2021.03.03.21252870 ◽

2021 ◽

Author(s):

Chiho Miyagawa ◽

Kosuke Murakami ◽

Takako Tobiume ◽

Takafumi Nonogaki ◽

Noriomi Matsumura

Keyword(s):

Clinical Trials ◽

Conservative Treatment ◽

Decision Tree ◽

Age At Diagnosis ◽

University Hospital ◽

Red Cross ◽

Decision Tree Analysis ◽

Tree Analysis ◽

Age Of Diagnosis

AbstractIntroductionHistorically, hysterectomy has been the radical treatment for adenomyosis. However, some patients do not wish to hysterectomy. Nevertheless, patients often required hysterectomy during the course of conservative treatment, but the factors involved remain unknown. The purpose of this study was to determine which patients can continue conservative treatment for adenomyosis.Materials and MethodsWe selected women diagnosed with adenomyosis and provided with conservative treatment at the Kindai University Hospital and Osaka Red Cross Hospital. Age at diagnosis, parity, uterine size, subtype of adenomyosis, type of conservative treatment, and timing of hysterectomy for cases with difficulty continuing conservative treatment were examined retrospectively.ResultsA total of 885 patients were diagnosed with adenomyosis, and 124 started conservative treatment. Conservative treatment was continued in 96 patients (77.4%) and hysterectomy was required in 28 patients (22.6%). The cumulative hysterectomy rate was 32.4%, and all women had hysterectomy within 63 months. In the decision tree analysis, 82% (23/28) of women aged 46 years or younger were able to continue conservative treatment when parity was zero or one. If parity was two and over, 95% (20/21) of those aged 39 years and older had hysterectomy.ConclusionsPatients that continue conservative treatment for approximately 5 years are more likely to have successful preservation of the uterus. Multipara and higher age of diagnosis are factors that contribute to hysterectomy after conservative treatment. Parity and age at diagnosis may be stratifying factor in future clinical trials on hormone therapy.

Download Full-text

The epidemiology of Moebius syndrome in Italy

Orphanet Journal of Rare Diseases ◽

10.1186/s13023-021-01808-2 ◽

2021 ◽

Vol 16 (1) ◽

Author(s):

Arturo Carta ◽

Stefania Favilla ◽

Giacomo Calzetti ◽

Maria Cristina Casalini ◽

Pier Francesco Ferrari ◽

...

Keyword(s):

Demographic Data ◽

Geographical Area ◽

National Level ◽

Age At Diagnosis ◽

University Hospital ◽

Italian Population ◽

Moebius Syndrome ◽

Cross Sectional ◽

Geographical Regions ◽

Chi Square Analysis

Abstract Background The epidemiology of Moebius syndrome (MBS) is difficult to assess. In the present study, we investigated the epidemiology of MBS in a well-defined population within a precise geographical area. Materials and methods Our university hospital is the only national referral center for the diagnosis and treatment of MBS. Participants in this cross-sectional study were patients affected by MBS who had been periodically followed by our medical staff since 1998. Most of the patients were referred to our hospital by the Italian Association of Moebius Syndrome (AISMO). Demographic data necessary for study purposes were made available in the AISMO database, updated to April 2018. Subjects were assigned to geographical macroareas that are conventionally used in surveys and epidemiological investigations by the Italian National Institute of Statistics. The rates and prevalence of MBS cases were calculated on the basis of the last available survey of the Italian population. Each study parameter was then calculated with reference to the whole country and macroarea partition. The sex rate and the corresponding prevalence were calculated with respect to the weighted whole population and to the respective sex population. Chi-square analysis was adopted to investigate possible differences among geographical regions and/or sexes. A p value < 0.05 was considered statistically significant. Results One hundred and sixty-four out of 212 MBS patients fulfilled our inclusion criteria. All cases occurred in Caucasian patients and were sporadic. The median age at diagnosis was 3.6 years, ranging from 0 to 55 years; this range was significantly reduced to 0–5 years (median age at diagnosis: 2.2 years) in patients included after 2007. The calculated prevalence at birth was 0.06 cases per 10,000 live births, with an overall prevalence of 0.27/100,000, without any sex or geographical predominance. Conclusions The prevalence of MBS observed herein, rounded for possible underestimation, was 0.3/100,000 people, without any regional difference in the distribution of cases. Our data confirm the rarity of the disease on a national level.

Download Full-text

Readiness to Participate in Psychiatric Research

The Canadian Journal of Psychiatry ◽

10.1177/070674370304800709 ◽

2003 ◽

Vol 48 (7) ◽

pp. 480-484 ◽

Cited By ~ 26

Author(s):

Daniele Zullino ◽

Philippe Conus ◽

François Borgeat ◽

Charles Bonsack

Keyword(s):

Clinical Trials ◽

Financial Incentive ◽

University Hospital ◽

Psychiatric Research ◽

Willingness To Participate ◽

Research Projects ◽

Hospital Physician ◽

Recruitment Process ◽

Consent Rate ◽

Retention Strategies

Background: The feasibility of clinical trials depends, among other factors, on the number of eligible patients, the recruitment process, and the readiness of patients to participate in research. Seeking patients' views about their experience in research projects may allow investigators to develop more effective recruitment and retention strategies. Methods: A total of 100 patients consecutively admitted to a psychiatric university hospital were interviewed with respect to their willingness to participate in a study. For a different study scenario, patients were asked whether they would be ready to participate if such a study were organized in the service and to indicate their reasons for refusing or for participating. Results: The general readiness to participate in a study ranged between 70% and 96%. The prospect of remuneration did not notably augment the potential consent rate. The most common and spontaneous motivation for agreeing to take part in a study was to help science progress and to allow future patients to benefit from improved diagnosis and treatment (87%). The presence or lack of a financial incentive was rarely chosen as an argument to agree (23%) or to refuse (7%) to participate. Patients relied mainly on their treating physicians when contemplating possible participation in a study (family physician [65%] and hospital physician [54%]). Conclusions: Clinicians and, in particular, treating doctors can play an important role in facilitating the recruitment process.

Download Full-text

Impact of hormone therapy on Medicare spending in the Women’s Health Initiative randomized clinical trials

American Heart Journal ◽

10.1016/j.ahj.2017.12.016 ◽

2018 ◽

Vol 198 ◽

pp. 108-114 ◽

Cited By ~ 2

Author(s):

Jacqueline B. Shreibati ◽

JoAnn E. Manson ◽

Karen L. Margolis ◽

Rowan T. Chlebowski ◽

Marcia L. Stefanick ◽

...

Keyword(s):

Clinical Trials ◽

Hormone Therapy ◽

Women’S Health ◽

Women's Health ◽

Randomized Clinical Trials ◽

Women's Health Initiative ◽

Women’S Health Initiative ◽

Health Initiative ◽

Medicare Spending ◽

The Women’S Health Initiative

Download Full-text

Analysis of Clinical Trials in Radiation Oncology: A Systematic Characterization of the Clinicaltrials.gov Database

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.05.1750 ◽

2014 ◽

Vol 90 (1) ◽

pp. S581-S582 ◽

Cited By ~ 3

Author(s):

N. Cihoric ◽

A. Tsikkinis ◽

D.M. Aebersold ◽

K. Lössl ◽

K. Zaugg

Keyword(s):

Clinical Trials ◽

Radiation Oncology

Download Full-text

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Annals of Oncology ◽

10.1093/annonc/mdv161 ◽

2015 ◽

Vol 26 (7) ◽

pp. 1280-1291 ◽

Cited By ~ 95

Author(s):

V. Bossuyt ◽

E. Provenzano ◽

W.F. Symmans ◽

J.C. Boughey ◽

C. Coles ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Residual Disease

Download Full-text

Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials

BJU International ◽

10.1046/j.1464-410x.1998.00730.x ◽

1998 ◽

Vol 82 (2) ◽

pp. 181-191 ◽

Cited By ~ 208

Author(s):

Berghmans ◽

Hendriks ◽

BO ◽

Hay-Smith ◽

de Bie ◽

...

Keyword(s):

Systematic Review ◽

Clinical Trials ◽

Urinary Incontinence ◽

Stress Urinary Incontinence ◽

Conservative Treatment ◽

Randomized Clinical Trials

Download Full-text

International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy

The Journal of Urology ◽

10.1016/j.juro.2018.08.044 ◽

2019 ◽

Vol 201 (2) ◽

pp. 284-291 ◽

Cited By ~ 5

Author(s):

Alejandro Berlin ◽

Fabio Y. Moraes ◽

Noelia Sanmamed ◽

Rachel Glicksman ◽

Alexander Koven ◽

...

Keyword(s):

Prostate Cancer ◽

Hormone Therapy ◽

Intermediate Risk ◽

Radical Treatment ◽

International Multicenter ◽

Multicenter Validation

Download Full-text

A review on phyto-pharmacology of Oxalis corniculata

Combinatorial Chemistry & High Throughput Screening ◽

10.2174/1386207324666210813121431 ◽

2021 ◽

Vol 24 ◽

Author(s):

Iqra Sarfraz ◽

Azhar Rasul ◽

Ghulam Hussain ◽

Muhammad Ajmal Shah ◽

Bushra Nageen ◽

...

Keyword(s):

Clinical Trials ◽

Biological Activities ◽

Chemical Constituents ◽

Current Effort ◽

Isolation And Characterization ◽

Anti Cancer ◽

Anti Oxidant ◽

Anti Fungal ◽

Warm Temperate

: Oxalis corniculata (Oxalidaceae) is a small decumbent and delicate appearing medicinal herb flourishing in warm temperate and tropical domains such as Pakistan and India. Main bioactive chemical constituents of Oxalis plant include several alkaloids, flavonoids, terpenoids, cardiac glycosides, saponins, phlobatannins along with steroids. Due to its polyphenolic, glycosides and flavonoid profile, it is proved to be protective in numerous ailments and exhibit various biological activities such as anti-fungal, anti-cancer, anti-oxidant, anti-bacterial, anti-diabetic, and cardioprotective. Moreover, bioactive phytochemicals from this plant possess significant wound healing potential. Our current effort intends to emphasize on the immense significance of this plant species, which have not been the subject matter of clinical trials and effective pharmacological studies, even though its favored usage has been stated. This review proposes that Oxalis corniculata possess potential for the cure of various diseases, however, further researches on isolation and characterization of bioactive compounds along with pre-clinical trials are compulsory to figure out its pharmacological applications.

Download Full-text